We develop drug candidates to advance into the clinic with pharmaceutical partners

We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities.

Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.

Our pipeline

We are inviting pharmaceutical partners to take all current and future candidates to clinical success.

Indication

 

C3 glomerulopathy (C3G)

 

Complement disorders

 

Complement disorders

Research

Preclinical

Phase I

Phase II

Compleva FH /CPV-101 (natural complement regulator)

Compleva MFHR1/CPV-102 (novel multi-level complement regulator)
Compleva FHL/CPV-103 (natural complement regulator)

Indication C3 glomerulopathy (C3G)

Compleva FH /CPV-101
(natural complement regulator)

Research

Preclinical

Phase I

Phase II

Indication Complement disorders

Compleva MFHR1/CPV-102
(novel multi-level complement regulator)

Research

Preclinical

Phase I

Phase II

Indication Complement disorders

Compleva FHL/CPV-103
(natural complement regulator)

Research

Preclinical

Phase I

Phase II

 

Fabry disease

 

Pompe disease

Repleva AGAL/RPV-001 (glyco-improved Fabry-ERT)

Repleva GAA/RPV-002 (glyco-improved Pompe-ERT)

Indication Fabry disease

Repleva AGAL/RPV-001 
(glyco-improved Fabry-ERT)

Research

Preclinical

Phase I

Phase II

Indication Pompe disease

Repleva GAA/RPV-002
(glyco-improved Pompe-ERT)

Research

Preclinical

Phase I

Phase II

Preclinical

Phase I

Phase II

Which product can we develop with you?

I consent to the processing of my personal data for the purpose of establishing contact in accordance with Article 6 paragraph 1 lit a of the Basic Data Protection Regulation (DSGVO).

In accordance with Article 13 of the Basic Data Protection Regulation (DSGVO), we would like to provide you with comprehensive information about the processing of your personal data. You can read all relevant information in our data protection policy.